Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| OCUL - Ocular Therapeutix | 12.10% | Hold | 6,480,000 | $10.00 | $65M |
| CLDX - Celldex Therapeutics | 9.91% | Hold | 985,000 | $53.85 | $53M |
| CDXS - Codexis | 5.84% | Hold | 1,345,000 | $23.26 | $31M |
| Chimerix | 5.82% | Hold | 5,030,000 | $6.19 | $31M |
| HROW - Harrow Health | 5.58% | Hold | 3,285,000 | $9.09 | $30M |
| Semler Scientific | 5.27% | Hold | 225,566 | $125.03 | $28M |
| BBIO - Bridgebio Pharma | 4.48% | Hold | 511,500 | $46.87 | $24M |
| CYTK - Cytokinetics | 3.87% | Hold | 580,000 | $35.74 | $21M |
| Protara Therapeutics | 3.31% | Hold | 2,558,472 | $6.92 | $18M |
| ETON - Eton Pharmaceuticals | 2.91% | Hold | 3,088,100 | $5.04 | $16M |
| Kiniksa Pharmaceuticals · CL A | 2.79% | Hold | 1,310,000 | $11.39 | $15M |
| Keros Therapeutics | 2.60% | Hold | 352,500 | $39.56 | $14M |
| STXS - Stereotaxis | 2.54% | Hold | 2,526,500 | $5.38 | $14M |
| Fortress Biotech | 2.26% | Hold | 3,750,000 | $3.22 | $12M |
| PRQR - Proqr Therapeutics | 2.23% | Hold | 1,424,200 | $8.37 | $12M |
| Sutro Biopharma | 1.90% | Hold | 537,800 | $18.89 | $10M |
| Tracon Pharmaceuticals | 1.82% | Hold | 2,518,371 | $3.87 | $10M |
| Macrogenics | 1.81% | Hold | 462,000 | $20.94 | $10M |
| LRMR - Larimar Therapeutics | 1.79% | Hold | 832,807 | $11.53 | $10M |
| PCVX - Vaxcyte | 1.67% | Hold | 353,400 | $25.37 | $9M |
| CRNX - Crinetics Pharmaceuticals | 1.58% | Hold | 402,113 | $21.05 | $8M |
| XOMA - XOMA Del | 1.56% | Hold | 338,350 | $24.75 | $8M |
| Neoleukin Therapeutics | 1.41% | Hold | 1,047,300 | $7.23 | $8M |
| Adamas Pharmaceuticals | 1.34% | Hold | 1,460,000 | $4.91 | $7M |
| Verastem | 1.34% | Hold | 2,325,000 | $3.08 | $7M |
| Holding | 1.30% | Hold | 205,381 | $33.98 | $7M |
| TELA - Tela Bio | 1.13% | Hold | 443,199 | $13.66 | $6M |
| PTGX - Protagonist Therapeutics | 1.09% | Hold | 330,222 | $17.72 | $6M |
| Acutus Medical | 0.97% | Hold | 590,000 | $8.84 | $5M |
| Optinose | 0.87% | Hold | 1,558,500 | $3.00 | $5M |
| Mei Pharma | 0.81% | Hold | 1,565,000 | $2.76 | $4M |
| Forma Therapeutics | 0.79% | Hold | 182,950 | $23.19 | $4M |
| Sierra Oncology | 0.68% | Hold | 165,778 | $21.92 | $4M |
| Avalo Therapeutics | 0.59% | Hold | 1,459,400 | $2.18 | $3M |
| FOLD - Amicus | 0.57% | Hold | 320,800 | $9.55 | $3M |
| Aveo Biosciences | 0.53% | Hold | 455,600 | $6.18 | $3M |
| Merus | 0.41% | Hold | 100,250 | $22.00 | $2M |
| Viracta Therapeutics | 0.39% | Hold | 258,556 | $8.02 | $2M |
| Sio Gene Therapies | 0.39% | Hold | 955,000 | $2.17 | $2M |
| Leap Therapeutics | 0.36% | Hold | 476,000 | $4.01 | $2M |
| Precision Biosciences | 0.35% | Hold | 163,900 | $11.54 | $2M |
| WHWK - Aadi Biosciences | 0.25% | Hold | 45,020 | $29.36 | $1M |
| Nucana | 0.23% | Hold | 479,600 | $2.58 | $1M |
| Aptose Biosciences | 0.22% | Hold | 549,000 | $2.18 | $1M |
| AKBA - Akebia Therapeutics | 0.17% | Hold | 311,300 | $2.88 | $897K |
| Selecta Biosciences | 0.08% | Hold | 106,000 | $4.16 | $441K |
| Cymabay Therapeutics | 0.08% | Hold | 115,015 | $3.65 | $420K |
| Biolinerx | 0.01% | Hold | 16,667 | $2.76 | $46K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2